Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | DNM2 | P50570 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14061139 | 0.94 | KDM1A (0.48) | KDM1APOLBHDAC3HDAC4HDAC1 | |
| SCHEMBL2276463 | 0.88 | KDM1A (0.50) | KDM1APOLBHDAC3HDAC4HDAC1 | |
| SCHEMBL3696937 | 0.80 | OXER1 (0.54) | — | |
| SCHEMBL28223276 | 0.79 | OXER1 (0.53) | — | |
| SCHEMBL4672103 | 0.77 | OXER1 (0.52) | — | |
| SCHEMBL4107082 | 0.76 | MAOA (0.68) | KDM1APOLBNPC1RAB9AMAOA | |
| SCHEMBL29445180 | 0.76 | MAOA (0.68) | KDM1APOLBNPC1RAB9AMAOA | |
| SCHEMBL1092961 | 0.75 | KDM1A (0.55) | KDM1APOLBNPC1RAB9A | |
| SCHEMBL29644192 | 0.73 | NPC1 (0.57) | POLBNPC1RAB9A | |
| SCHEMBL28738947 | 0.73 | NPC1 (0.57) | POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-20070244198-A1 | Carboxylic Derivatives | LI LANNA | 2007-10-18 | — | — | US | disclosed |
| US-20060258866-A1 | Carboxylic derivates | ASTRAZENECA AB, A SWEDEN CORPORATION | 2006-11-16 | — | — | US | disclosed |
| EP-1676833-A1 | Propionic acid derivatives useful in the treatment of lipid disorders | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244198-A1 | Carboxylic Derivatives | GPR119, CPT1A, PC | KDM1A 2422/4885POLB 3894/4885DNM2 2230/4885 |
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | GPR119, PPARA, PPARG | KDM1A 3248/4885POLB 2597/4885DNM2 1876/4885 |
| US-20060258866-A1 | Carboxylic derivates | GPR119, PC, CPT1A | KDM1A 1188/4885POLB 3949/4885DNM2 1764/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | KDM1A 4613/4885POLB 4022/4885DNM2 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.